Canadian court upholds data exclusivity rules for innovators
This article was originally published in SRA
The Canadian Federal Court has upheld the government’s enactment of data protection regulations that provide up to eight years of protection for innovative drugs and the possibility of a further six months if studies are conducted in the paediatric population1-3.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.